Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer
US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs Novo Nordisk has launched a surprise $9bn (£6.9bn) offer for the US obesity-focused biotech firm Metsera that could gazump an existing bid from Pfizer as the pharmaceutical giants fight for (…)
Site référencé:
The Guardian
5600.jpg?width=140&quality=85&auto=format&fit=max&s=3c9fbe44095ac082c7d3ab69690c3997, 5600.jpg?width=460&quality=85&auto=format&fit=max&s=cfb59dc39e88893fa40a3c4f100554b7, 5600.jpg?width=700&quality=85&auto=format&fit=max&s=a68123dfb611648b76cc65a9b7551f47
The Guardian
Wayne McGregor review : shimmering dance spectacular without a live dancer in sight
30/10/2025
‘We are both freedom fighters’ : Africa exhibition at war-damaged Kyiv gallery strikes a chord
30/10/2025
‘She called me a silly boy ! Lovely lady !’ Your treasured memories of Prunella Scales
30/10/2025
Birmingham city council was probably never bankrupt, says accountancy expert
30/10/2025
‘It’s about playing football’ : how Fabio Borini landed at League Two Salford
30/10/2025
Toxin levels in fish lead to calls for UK-wide ban on mercury dental fillings
30/10/2025